NO20003256L - ACE inhibitor-MMP inhibitor kombinasjoner - Google Patents

ACE inhibitor-MMP inhibitor kombinasjoner

Info

Publication number
NO20003256L
NO20003256L NO20003256A NO20003256A NO20003256L NO 20003256 L NO20003256 L NO 20003256L NO 20003256 A NO20003256 A NO 20003256A NO 20003256 A NO20003256 A NO 20003256A NO 20003256 L NO20003256 L NO 20003256L
Authority
NO
Norway
Prior art keywords
inhibitor
combinations
mmp
ace
ace inhibitor
Prior art date
Application number
NO20003256A
Other languages
English (en)
Other versions
NO20003256D0 (no
Inventor
Jr Joseph Thomas Peterson
Milton Lethan Pressler
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22083543&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20003256(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of NO20003256D0 publication Critical patent/NO20003256D0/no
Publication of NO20003256L publication Critical patent/NO20003256L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO20003256A 1997-12-23 2000-06-22 ACE inhibitor-MMP inhibitor kombinasjoner NO20003256L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6859497P 1997-12-23 1997-12-23
PCT/US1998/023993 WO1999032150A1 (en) 1997-12-23 1998-11-10 Ace inhibitor-mmp inhibitor combinations

Publications (2)

Publication Number Publication Date
NO20003256D0 NO20003256D0 (no) 2000-06-22
NO20003256L true NO20003256L (no) 2000-06-22

Family

ID=22083543

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20003256A NO20003256L (no) 1997-12-23 2000-06-22 ACE inhibitor-MMP inhibitor kombinasjoner

Country Status (24)

Country Link
US (1) US6133304A (no)
EP (1) EP1047450B1 (no)
JP (1) JP2001526245A (no)
KR (1) KR20010033473A (no)
AR (1) AR015504A1 (no)
AT (1) ATE225187T1 (no)
AU (1) AU751701B2 (no)
BR (1) BR9814422A (no)
CA (1) CA2305436A1 (no)
CO (1) CO4970775A1 (no)
DE (1) DE69808518T2 (no)
DK (1) DK1047450T3 (no)
ES (1) ES2184340T3 (no)
HU (1) HUP0100427A3 (no)
IL (1) IL135428A0 (no)
IS (1) IS5446A (no)
NO (1) NO20003256L (no)
NZ (1) NZ503962A (no)
PE (1) PE20000065A1 (no)
PL (1) PL341335A1 (no)
PT (1) PT1047450E (no)
UY (1) UY25321A1 (no)
WO (1) WO1999032150A1 (no)
ZA (1) ZA9811794B (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA01008857A (es) * 1999-03-03 2002-07-02 Procter & Gamble Inhibidores de metaloproteasa dihetero sustituidos.
US6376524B1 (en) 2000-06-21 2002-04-23 Sunesis Pharmaceuticals, Inc. Triphenyl compounds as interleukin-4 antagonists
GB0100761D0 (en) 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
CA2436130A1 (en) 2001-01-29 2002-08-08 Ortho-Mcneil Pharmaceutical, Inc. Substituted indoles and their use as integrin antagonists
DE10125882B4 (de) * 2001-05-28 2007-03-29 Esparma Gmbh Arzneimittel enthaltend Ambroxol, dessen Salze und/oder Prodrugs zusammen mit α-Liponsäure im Rahmen der Behandlung des Diabetes mellitus
CA2457033A1 (en) * 2001-08-20 2003-02-27 Ono Pharmaceutical Co., Ltd. A medecine for cardiac failure
GB0212412D0 (en) * 2002-05-29 2002-07-10 Novartis Ag Combination of organic compounds
US7071211B2 (en) * 2002-09-27 2006-07-04 Bausch & Lomb Inc. Small organic molecules that increase the activity of gelatinase a in ocular cells
CA2501282C (en) * 2002-10-04 2012-12-04 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Vasoregulating compounds and methods of their use
JP5068428B2 (ja) * 2002-11-07 2012-11-07 アメリカ合衆国 血管新生および抗血管新生療法のための標的
AU2003300076C1 (en) 2002-12-30 2010-03-04 Angiotech International Ag Drug delivery from rapid gelling polymer composition
EP2287326A1 (en) 2003-08-08 2011-02-23 Arriva Pharmaceuticals, Inc. Methods of protein production in yeast
ATE530165T1 (de) * 2003-11-14 2011-11-15 Baxter Int Alpha1-antitrypsin-zusammensetzungen und behandlungsverfahren unter verwendung dieser zusammensetzungen
EP1737499A4 (en) 2004-03-09 2009-07-22 Arriva Pharmaceuticals Inc TREATMENT OF CHRONIC OBSTRUCTIVE LUNG DISEASE BY INHALATION OF LOW DOSES OF A PROTEASE HEMMER
JP2008508348A (ja) * 2004-08-02 2008-03-21 ジェンメディカ・セラピューティックス・ソシエダッド・リミターダ 銅含有アミンオキシダーゼを阻害するための化合物およびその使用
CN100367956C (zh) * 2006-08-29 2008-02-13 陈俊云 用于治疗高血压的药物
JP2011525194A (ja) * 2008-06-20 2011-09-15 キネメッド， インコーポレイテッド 線維性疾患または病態を治療するための組成物
WO2010011302A1 (en) * 2008-07-22 2010-01-28 Chdi, Inc. Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
CA2774389A1 (en) * 2009-10-01 2011-04-07 Symphony Evolution, Inc. Methods of treating aneurysmal dilatation, blood vessel wall weakness and specifically abdominal aortic and thoracic aneurysm using matrix metalloprotease-2 inhibitors
KR20140072037A (ko) 2011-08-30 2014-06-12 씨에이치디아이 파운데이션, 인코포레이티드 키뉴레닌-3-모노옥시게나제 억제제, 약학적 조성물 및 이의 사용 방법
SI2750677T1 (sl) 2011-08-30 2017-10-30 Chdi Foundation, Inc. Inhibitorji kinurenin-3-monooksigenaze, farmacevtski sestavki in postopki njihove uporabe
WO2014210062A1 (en) 2013-06-26 2014-12-31 Stealth Peptides International, Inc. Methods for the regulation of matrix metalloproteinase expression
AU2015289492B2 (en) 2014-07-17 2020-02-20 Chdi Foundation, Inc. Methods and compositions for treating HIV-related disorders
WO2017117130A1 (en) 2015-12-28 2017-07-06 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for inhibiting human immunodeficiency virus (hiv) release from infected cells

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0527879T3 (da) * 1990-05-11 1997-07-14 Pfizer Synergistiske terapeutiske præparater og fremgangsmåder.
EP1136078A3 (en) * 1995-02-10 2002-07-24 G.D. Searle & Co. Combination of angiotensin converting enzyme inhibitor and side- effect-reduced amount of aldosterone antagonist
CN1077885C (zh) * 1996-05-17 2002-01-16 沃尼尔·朗伯公司 联苯基磺酰胺基质金属蛋白酶抑制剂
US5756545A (en) * 1997-04-21 1998-05-26 Warner-Lambert Company Biphenysulfonamide matrix metal alloproteinase inhibitors

Also Published As

Publication number Publication date
PL341335A1 (en) 2001-04-09
AU751701B2 (en) 2002-08-22
ATE225187T1 (de) 2002-10-15
DK1047450T3 (da) 2003-01-27
NO20003256D0 (no) 2000-06-22
HUP0100427A2 (hu) 2001-06-28
JP2001526245A (ja) 2001-12-18
HUP0100427A3 (en) 2002-11-28
KR20010033473A (ko) 2001-04-25
AU1522099A (en) 1999-07-12
DE69808518D1 (de) 2002-11-07
DE69808518T2 (de) 2003-06-26
ZA9811794B (en) 1999-06-29
IL135428A0 (en) 2001-05-20
WO1999032150A1 (en) 1999-07-01
EP1047450A1 (en) 2000-11-02
PT1047450E (pt) 2003-02-28
NZ503962A (en) 2002-03-28
ES2184340T3 (es) 2003-04-01
CA2305436A1 (en) 1999-07-01
UY25321A1 (es) 2004-07-30
CO4970775A1 (es) 2000-11-07
BR9814422A (pt) 2000-10-10
EP1047450B1 (en) 2002-10-02
US6133304A (en) 2000-10-17
IS5446A (is) 2000-04-14
PE20000065A1 (es) 2000-02-11
AR015504A1 (es) 2001-05-02

Similar Documents

Publication Publication Date Title
DK0958287T3 (da) Sulfamidmetalloprotease-inhibitorer
DK1027332T3 (da) Hidtil ukendte lactametalloproteaseinhibitorer
NO995433D0 (no) Protease-inhibitorer
NO20003256D0 (no) ACE inhibitor-MMP inhibitor kombinasjoner
ID19198A (id) Inhibitor metaloprotease heterosiklik
DK1004669T3 (da) Hidtil ukendte differentieringsinhibitor
DK1344524T3 (da) Refluksinhibitorer
ID18416A (id) Inhibitor metaloprotease diheterosiklik
FI951553L (fi) 1H-indoli-glyoksyyliamidi-sPLA2-inhibiittoreita
FI963597L (fi) Isoprenyylitransferaasi-inhibiittoreita
NO972930D0 (no) Fibronectin-adhesjonsinhibitorer
FI972160A0 (fi) Matriisimetalloproteaasi-inhibiittorit
NO995435D0 (no) Protease-inhibitorer
NO995268D0 (no) Proteaseinhibitorer
NO995434L (no) Proteaseinhibitorer
ID18417A (id) Inhibitor ditentat metaloprotease
ID17792A (id) Penghambat penghambat metaloproreinase matriks
ATE252547T1 (de) Matrixmetalloproteinaseinhibitoren
NO20001835D0 (no) WOF inhibitor
DE69828361D1 (de) Apoptose-inhibitor
DE69720957T2 (de) Ace-hemmer
EP1007548A4 (en) THROMBIN INHIBITOR FROM TSE-TSE FLY
NO974892L (no) Ventilasjonsr°r
MA26429A1 (fr) Inhibiteurs de protease
SI1047450T1 (en) Ace inhibitor-mmp inhibitor combinations

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application